aberrant cell communication, aiming to maximize on-target activity while minimizing off-target toxicity. Dysruptx applies this approach at early stages of drug discovery to address mechanisms that commonly contribute to clinical-stage failures. The platform is oriented toward generating precision peptide medicines for hard-to-treat cancers and other serious human diseases where selective modulation of complex biological networks is required. Dysruptx also positions its technology for collaboration with pharmaceutical and biotechnology partners engaged in precision therapeutics and platform-driven discovery.